Overall, while GLP‐1 RAs appear safe and beneficial in HFpEF with obesity, they should be used cautiously in patients with reduced LVEF until more definitive evidence becomes available. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.